Skip to main content
. 2020 Jan 30;10:930. doi: 10.3389/fendo.2019.00930

Figure 2.

Figure 2

βE2 treatment prevented PCSK9-mediated LDLR degradation in HepG2 cells. (A) βE2 treatment increases the fluorescence intensity of LDLR, as determine by immunofluorescence assay. The relative fluorescent unit (RFU) of LDLR was determined by ZEISS 2010 software. (B) βE2 treatment increased LDLR protein levels in the presence of rhPCSK9 (25 μg/mL) by Western blot analysis. (C) qPCR was used to examine the mRNA levels of LDLR in the HepG2 cells treated with βE2 for 6 h in the presence of rhPCSK9 (25 μg/mL). The β-actin value was used to normalize the qPCR results. Values represent the means ± SEM, n = 3; *P < 0.05 for a comparison between two groups.